JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.0925
Heidi L Rehm
{"title":"Building Biobanks to Drive Biomedical Research and Genomically Informed Care.","authors":"Heidi L Rehm","doi":"10.1001/jamanetworkopen.2025.0925","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.0925","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250925"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.2377
Jé Judson, Jaquelyn L Jahn
{"title":"Strengthening Surveillance of Fatal Police Violence for Accountability and Racial Justice.","authors":"Jé Judson, Jaquelyn L Jahn","doi":"10.1001/jamanetworkopen.2025.2377","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.2377","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e252377"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1421
Todd C Lee, Connor J Prosty, Michael Fralick, Angela Huttner, Emily G McDonald, José Molina, Mical Paul, Ruxandra Pinto, Asgar Rishu, Elodie von Dach, Dafna Yahav, Rob Fowler, Nick Daneman
{"title":"Seven vs Fourteen Days of Antibiotics for Gram-Negative Bloodstream Infection: A Systematic Review and Noninferiority Meta-Analysis.","authors":"Todd C Lee, Connor J Prosty, Michael Fralick, Angela Huttner, Emily G McDonald, José Molina, Mical Paul, Ruxandra Pinto, Asgar Rishu, Elodie von Dach, Dafna Yahav, Rob Fowler, Nick Daneman","doi":"10.1001/jamanetworkopen.2025.1421","DOIUrl":"10.1001/jamanetworkopen.2025.1421","url":null,"abstract":"<p><strong>Importance: </strong>Gram-negative bloodstream infections are a common cause of hospitalization. A 2-week duration of antibiotic therapy has been commonly used, but shorter durations may have similar outcomes.</p><p><strong>Objectives: </strong>To assess whether 7 days of antibiotic therapy was noninferior to 14 days.</p><p><strong>Data sources: </strong>Starting with a 2022 individual patient data meta-analysis, PubMed, Cochrane Central Register of Controlled Trials, and Web of Science were searched to identify additional eligible randomized clinical trials (RCTs) conducted from May 1, 2022, until November 30, 2024.</p><p><strong>Study selection: </strong>RCTs involving primarily adults who were hospitalized at the time of Gram-negative bloodstream infection and were allocated to 7 or 14 days of antibiotic therapy. Studies were independently reviewed by 2 investigators.</p><p><strong>Data extraction and synthesis: </strong>PRISMA guidelines were followed. Data were extracted by 2 investigators. Any unpublished data were obtained directly from study authors. Risk of bias and certainty of the evidence were assessed in duplicate using the Cochrane Risk of Bias Tool, version 2, and the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled by separate random-effects meta-analyses for the intention-to-treat (ITT) and per-protocol (PP) populations. A noninformative prior probability was used for the effect, and an evidence-based weakly informative prior probability was used for heterogeneity. Risk ratios (RRs), 95% credible intervals (CrIs), and probability of noninferiority were calculated using a prespecified upper bound of 1.25 or less.</p><p><strong>Main outcomes and measures: </strong>Ninety-day all-cause mortality.</p><p><strong>Results: </strong>Four eligible RCTs contributed 3729 patients in the ITT population (1912 women [51.3%]; median age range, 67-79 years) and 3126 in the PP population. In the ITT analysis, within 90 days, 226 patients (12.8%) receiving 7 days of antibiotics died compared with 253 (13.7%) receiving 14 days, corresponding to an RR for 90-day mortality of 0.91 (95% CrI, 0.69-1.22) and a 97.8% probability of noninferiority. In the PP analysis, the RR was 0.93 (95% CrI, 0.68-1.32), corresponding to a 95.1% probability of noninferiority.</p><p><strong>Conclusions and relevance: </strong>In this systematic review and meta-analysis of patients with Gram-negative bloodstream infections and adequate source control, 7 days of antibiotic therapy had a high probability of being noninferior to 14 days. These findings support a shorter duration of antibiotic therapy for appropriately selected patients like those in the included RCTs.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251421"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1333
Peter W Schreiber, Linard D Hoessly, Katia Boggian, Dionysios Neofytos, Christian van Delden, Adrian Egli, Michael Dickenmann, Cédric Hirzel, Oriol Manuel, Michael Koller, Simona Rossi, Vanessa Banz, Philippe Compagnon, Philipp Dutkowski, Andreas E Kremer, Annalisa Berzigotti, Julien Vionnet, Nicolas Goossens, David Semela, Patrizia Künzler-Heule, Christine Bernsmeier, Stefan P Kuster, Susanne Stampf, Nicolas J Mueller
{"title":"Surgical Site Infections, Risk Factors, and Outcomes After Liver Transplant.","authors":"Peter W Schreiber, Linard D Hoessly, Katia Boggian, Dionysios Neofytos, Christian van Delden, Adrian Egli, Michael Dickenmann, Cédric Hirzel, Oriol Manuel, Michael Koller, Simona Rossi, Vanessa Banz, Philippe Compagnon, Philipp Dutkowski, Andreas E Kremer, Annalisa Berzigotti, Julien Vionnet, Nicolas Goossens, David Semela, Patrizia Künzler-Heule, Christine Bernsmeier, Stefan P Kuster, Susanne Stampf, Nicolas J Mueller","doi":"10.1001/jamanetworkopen.2025.1333","DOIUrl":"10.1001/jamanetworkopen.2025.1333","url":null,"abstract":"<p><strong>Importance: </strong>Surgical site infections (SSIs) are one of the most common health care-associated infections. Surgical site infections can have harmful effects in liver transplant (LT) recipients.</p><p><strong>Objective: </strong>To assess the incidence of SSI after LT and identify risk factors associated with SSIs and whether SSIs are associated with death and graft loss.</p><p><strong>Design, setting, and participants: </strong>A multicenter cohort study encompassing data on LT performed at all Swiss transplant centers between May 1, 2008, and September 30, 2020, was conducted. Data analyses were performed in 2023.</p><p><strong>Exposure: </strong>Liver transplant.</p><p><strong>Main outcomes and measures: </strong>Frequency of SSIs within 90 days after transplant, risk factors associated with SSIs, and association of SSIs with 1-year death or graft loss. Surgical site infections were defined according to Centers for Disease Control and Prevention criteria with SSIs occurring within 90 days after LT. For association with posttransplant outcomes, 1-year follow-up data were analyzed.</p><p><strong>Results: </strong>Among 1333 LT recipients in the Swiss Transplant Cohort Study, 1158 adults were included in analyses. Median age was 57.2 (IQR, 49.3-62.8) years and 792 were men (68.4%). Seventy patients (6.0%) had an SSI. Most SSIs were deep incisional (9 [12.8%]) or organ-space infections (54 [77.1%]). In most SSIs (56 [80.0%]), bacteria were detected, most frequently Enterococcus spp (36 of 75 [48.0%]) and Escherichia coli (12 of 75 [16.0%]). In multivariable analysis, prior liver transplant (odds ratio [OR] 4.01; 95% CI, 1.44-11.18; P = .008) and living liver donation (OR, 4.08; 95% CI, 1.37-12.16; P = .01) were independent risk factors associated with SSIs. Surgical site infections were independently associated with graft loss and/or death (hazard ratio [HR], 3.24; 95% CI, 1.82-5.79; P < .001); this association was observed in separate analyses on graft loss (HR, 2.97; 95% CI, 1.32-6.68; P = .02) and death (HR, 3.25; 95% CI, 1.44-7.35; P = .01).</p><p><strong>Conclusions and relevance: </strong>The findings of this study suggest that prior liver transplant and living liver donation are independent risk factors associated with SSIs and that SSIs are independently associated with graft loss and/or death, highlighting the relevance of this health care-associated infection.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251333"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1100
Chanu Rhee, Sarah E Train, Michael R Filbin, Steven T Park, Nicholas M Mohr, Anne Zepeski, Brett A Faine, David J Roach, Emily Porter, Claire N Shappell, Kamryn Plechot, Laura DelloStritto, Tingting Yu, Michael Klompas
{"title":"Complex Sepsis Presentations, SEP-1 Compliance, and Outcomes.","authors":"Chanu Rhee, Sarah E Train, Michael R Filbin, Steven T Park, Nicholas M Mohr, Anne Zepeski, Brett A Faine, David J Roach, Emily Porter, Claire N Shappell, Kamryn Plechot, Laura DelloStritto, Tingting Yu, Michael Klompas","doi":"10.1001/jamanetworkopen.2025.1100","DOIUrl":"10.1001/jamanetworkopen.2025.1100","url":null,"abstract":"<p><strong>Importance: </strong>The Centers for Medicare & Medicaid Services Severe Sepsis and Septic Shock Management Bundle (SEP-1) is supported by observational studies that report SEP-1 compliance is associated with lower mortality. Most studies, however, adjusted for limited confounders and provided little insight into why bundle-compliant care was not provided.</p><p><strong>Objectives: </strong>To identify the clinical factors that complicate the diagnosis and management of sepsis and assess their association with SEP-1 compliance and mortality.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study was conducted among 590 adults with sepsis in the emergency department of 4 academic hospitals from January 1, 2019, to December 31, 2022. Patients' medical records were reviewed between September 2022 and December 2023.</p><p><strong>Main outcomes and measures: </strong>Study outcomes were (1) characteristics of patients who received SEP-1-compliant care vs characteristics of patients who received noncompliant care and (2) association between SEP-1 compliance and hospital mortality using multivariable models to adjust for successively more potential confounders (first demographics and comorbidities, then infection source, then severity of illness, and then clinical markers of complexity).</p><p><strong>Results: </strong>Of 590 patients with sepsis (median age, 65 years [IQR, 53-77 years]; 329 men [55.8%]), 335 (56.8%) received SEP-1-compliant care, and 225 (43.2%) received noncompliant care. Compared with patients in the compliant group, patients in the noncompliant group were more likely to be 65 years or older (142 [55.7%] vs 158 [47.2%]; odds ratio [OR], 1.41 [95% CI, 1.01-1.95]), to have multiple comorbidities (Elixhauser score >20: 99 [38.8%] vs 99 [29.6%]; OR, 1.51 [95% CI, 1.07-2.13]), and to have a higher incidence of septic shock (107 [42.0%] vs 107 [31.9%]; OR, 1.54 [95% CI, 1.10-2.16]), kidney dysfunction (87 [34.1%] vs 80 [23.9%]; OR, 1.65 [95% CI, 1.15-2.37]), and thrombocytopenia (43 [16.9%] vs 37 [11.0%]; OR, 1.16 [95% CI, 1.02-2.62]) on presentation. Compared with patients in the compliant group, those in the noncompliant group also had more nonfebrile presentations (136 [53.3%] vs 121 [36.1%]; OR, 2.02 [95% CI, 1.45-2.82]), impaired mental status (92 [36.1%] vs 94 [28.1%]; OR, 1.45 [95% CI, 1.02-2.05]), need for bedside procedures (57 [22.4%] vs 41 [12.2%]; OR, 2.06 [95% CI, 1.33-3.21]), acute concurrent noninfectious illnesses (140 [54.9%] vs 151 [45.1%]; OR, 1.48 [95% CI, 1.07-2.06]), and noninfectious illness as the primary factor associated with their presentation (84 [32.9%] vs 71 [21.2%]; OR, 1.82 [95% CI, 1.08-3.08]). SEP-1 compliance was associated with lower crude mortality rates compared with noncompliance (40 [11.9%] vs 41 [16.1%]; unadjusted OR, 0.60 [95% CI, 0.37-0.98]), but there was no statistically significant difference between groups after successively adjusting for demograp","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251100"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1092
Miriam H Beauchamp, Ken Tang, Andrée-Anne Ledoux, Ashley D Harris, Kristina A Kowalski, William R Craig, Jocelyn Gravel, Quynh Doan, Stephen B Freedman, Roger L Zemek, Keith Owen Yeates
{"title":"Optimal Recovery Following Pediatric Concussion.","authors":"Miriam H Beauchamp, Ken Tang, Andrée-Anne Ledoux, Ashley D Harris, Kristina A Kowalski, William R Craig, Jocelyn Gravel, Quynh Doan, Stephen B Freedman, Roger L Zemek, Keith Owen Yeates","doi":"10.1001/jamanetworkopen.2025.1092","DOIUrl":"10.1001/jamanetworkopen.2025.1092","url":null,"abstract":"<p><strong>Importance: </strong>Pediatric concussion affects millions and results in heterogeneous outcomes and recovery trajectories. Given favorable outcome for most children, it is useful to understand characteristics of positive outcome to promote full recovery in all children.</p><p><strong>Objective: </strong>To document the timeframe of recovery to optimal functioning, defined comprehensively across motor-physical, cognitive, socioemotional, and resilience-support domains, after concussion among children ages 8 to 16 years.</p><p><strong>Design, setting, and participants: </strong>For this prospective cohort study, children ages 8 to 16.99 years with a concussion or orthopedic injury (OI) were recruited between September 2016 and July 2019 from 5 Pediatric Emergency Research Canada emergency departments and assessed approximately 10 days, 3 months, and 6 months after their injury. Data were analyzed from January 29, 2024, to January 11, 2025.</p><p><strong>Exposure: </strong>Concussion.</p><p><strong>Main outcomes and measures: </strong>Participants completed self-report and direct assessment measures of postconcussive symptoms, physical activity and function, balance, cognitive function, quality of life, resilience, and social support. The main outcome was optimal functioning, which was derived from 11 variables and criteria indicative of absence of impairment and average or above functioning in each domain (overall score, 0-11; higher score indicates better function). A longitudinal, multivariable, cumulative probability ordinal regression model was fitted to examine factors associated with optimal functioning.</p><p><strong>Results: </strong>A total of 967 children (median [IQR] age, 12.3 [10.5-14.3] years; 562 [58.1%] male) were enrolled, including 633 children with a concussion and 334 children with an OI. The median (IQR) optimal functioning scores for the OI group were 6.0 (4.0-8.0) at 10 days, 7.0 (5.0-9.0) at 3 months, and 7 (5.0-9.0) at 6 months, compared with 4.0 (2.0-6.0) at 10 days, 6.0 (4.0-9.0) at 3 months, and 7.0 (4.0-9.0) at 6 months in the concussion group. The 3 main variables (time, sex, and group) were significantly associated with optimal functioning, as were all 2-way interactions. Time was the strongest factor associated with optimal functioning (Wald χ258 = 485.11; P < .001), followed by group (Wald χ26 = 95.10; P < .001), and sex (Wald χ26 = 23.19; P < .001). At the 10-day follow-up, concussion was associated with lower optimal functioning than OI among females (odds ratio [OR], 0.24 [95% CI, 0.16-0.36]) and males (OR, 0.37 [95% CI, 0.26-0.53]). This difference persisted for females at 3 months (OR, 0.57 [95% CI, 0.35-0.93]) but not for males. Optimal functioning was comparable at 6 months.</p><p><strong>Conclusions and relevance: </strong>In this prospective cohort study of children with concussion, achieving optimal functioning levels across physical, cognitive, socioemotional, and resilience domains took 3 mo","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251092"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1131
Adrian D Haimovich, Suzanne M Bertisch, Venkat Jegadeesan, Jennifer P Stevens, Mara A Schonberg, Sarah D Berry
{"title":"Sleep Interruptions Among Older Adults Admitted to the Hospital.","authors":"Adrian D Haimovich, Suzanne M Bertisch, Venkat Jegadeesan, Jennifer P Stevens, Mara A Schonberg, Sarah D Berry","doi":"10.1001/jamanetworkopen.2025.1131","DOIUrl":"10.1001/jamanetworkopen.2025.1131","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251131"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.0972
Eun Hye Oh, Jae-Hwan Choi, Hyun Sung Kim, Seo Young Choi, Hyun Ah Kim, Hyung Lee, In Soo Moon, Ji-Yun Park, Byeol-A Yoon, Sang Ho Kim, Jeong-Yeon Kim, Hyo Jung Kim, Kwang-Dong Choi
{"title":"Treatment Maneuvers in Cupulolithiasis of the Posterior Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial.","authors":"Eun Hye Oh, Jae-Hwan Choi, Hyun Sung Kim, Seo Young Choi, Hyun Ah Kim, Hyung Lee, In Soo Moon, Ji-Yun Park, Byeol-A Yoon, Sang Ho Kim, Jeong-Yeon Kim, Hyo Jung Kim, Kwang-Dong Choi","doi":"10.1001/jamanetworkopen.2025.0972","DOIUrl":"10.1001/jamanetworkopen.2025.0972","url":null,"abstract":"<p><strong>Importance: </strong>Head-shaking and mastoid oscillation maneuvers effectively treat cupulolithiasis of horizontal canal benign paroxysmal positional vertigo. However, to date there are no validated treatments for cupulolithiasis of posterior canal benign paroxysmal positional vertigo (PC-BPPV-cu).</p><p><strong>Objective: </strong>To determine the immediate and short-term therapeutic efficacy of head-shaking and mastoid oscillation maneuvers in PC-BPPV-cu.</p><p><strong>Design, setting, and participants: </strong>This double-blind randomized clinical trial was conducted at 6 referral-based university hospitals in South Korea between November 1, 2019, and April 30, 2023. The inclusion criteria consisted of (1) repetitive episodes of positional vertigo or dizziness; (2) positional nystagmus beating torsionally with the upper pole of the eye to the lower ear and vertically upward (to the forehead) and lasting longer than 1 minute, which was evoked by Dix-Hallpike or half Dix-Hallpike maneuver; and (3) absence of accompanying neurologic symptoms or signs suggesting central nervous system disorders. Patients were excluded who declined to participate or had cervical spine problems, multicanal BPPV, or cognitive dysfunction.</p><p><strong>Interventions: </strong>Patients were randomly assigned to the head-shaking, mastoid oscillation, or sham maneuver groups. After a maximum of 2 trials of each maneuver, therapeutic response was assessed within 30 minutes and the following day.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the short-term resolution rate of positional vertigo and nystagmus the following day. The secondary outcome was the immediate efficacy of 2 trials of each maneuver within 30 minutes.</p><p><strong>Results: </strong>A total of 159 patients were included in the analysis (108 [67.9%] women; mean [SD] age, 65.4 [10.5] years). Fifty-three participants were randomized to the head-shaking group (mean [SD] age, 64.0 [11.2] years; 33 [62.3%] women), 53 to the mastoid oscillation group (mean [SD], age, 66.5 [11.1] years; 41 [77.4%] women), and 53 to the control group (mean [SD] age, 65.6 [9.2] years; 34 [64.2%] women). A total of 142 patients (89.3%) completed the assessment the following day. In the intention-to-treat analysis, 20 patients in the head-shaking group (37.7%), 14 in the mastoid oscillation group (26.4%), and 7 in the control group (13.2%) showed the resolution of vertigo and nystagmus the following day (χ2 = 8.40; odds ratio, 2.86; 95% CI, 1.32-6.18; P = .004; α = .0167). For the secondary outcome (the immediate effectiveness of 2 trials of each maneuver compared with sham within 30 minutes), no significant difference was detected (6 of 53 [11.3%] vs 4 of 53 [7.5%] vs 2 of 53 [3.8%]; P = .34; α = .05).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, the head-shaking maneuver was effective in the treatment of PC-BPPV-cu.</p><p><strong>Trial registration","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250972"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.1258
Ahmed Bentridi, Marie-France Giroux, Gilles Soulez, Louis Bouchard, Pierre Perreault, Audrey Chouinard, Marc Dorais, Ricardo Do Amaral, Pascaline Bernier, Eric Therasse
{"title":"Midline Venous Catheter vs Peripherally Inserted Central Catheter for Intravenous Therapy: A Randomized Clinical Trial.","authors":"Ahmed Bentridi, Marie-France Giroux, Gilles Soulez, Louis Bouchard, Pierre Perreault, Audrey Chouinard, Marc Dorais, Ricardo Do Amaral, Pascaline Bernier, Eric Therasse","doi":"10.1001/jamanetworkopen.2025.1258","DOIUrl":"10.1001/jamanetworkopen.2025.1258","url":null,"abstract":"<p><strong>Importance: </strong>Peripherally inserted central catheters (PICCs) are frequently used for peripheral intravenous therapy (IVT) that could be administered through a peripheral midline venous catheter (MVC).</p><p><strong>Objective: </strong>To assess the noninferiority of MVCs compared with PICCs as a reliable vascular access for peripheral IVT and blood draws for IVT that does not require a central VC.</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conducted in a single tertiary care center from September 2018 to March 2022. Participants were all consecutive adult patients who were referred for PICC and eligible for MVC. Patients likely to require a central VC (those in the critical care unit, those with kidney failure, or those requiring a multilumen VC) were excluded. Analyses were based on the evaluable population.</p><p><strong>Interventions: </strong>Participants were randomized 1:1 to either MVC or PICC. For the MVC group, a 20-cm-long, 4F (French), single-lumen MVC without a valve was used without fluoroscopic assistance. For the PICC group, a 4F, single-lumen PICC without a valve was positioned under fluoroscopy at the cavoatrial junction.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the percentage of patients without VC-related adverse events or dysfunctions requiring medical intervention during follow-up. A noninferiority test was performed to compare the proportion of adverse events or dysfunctions between the MVC and PICC groups. A noninferiority margin was set at 10% and a 5% 1-sided significance level.</p><p><strong>Results: </strong>Of the 6821 patients referred to the tertiary care center for PICC insertion, 294 (180 males [61.2%]; median [IQR] age, 56.3 [38.2-66.7] years) were randomized to receive MVCs (n = 146) or PICCs (n = 148); 135 and 137 participants, respectively, were included in data analysis after exclusion of those who did not complete follow-up. Ninety of 135 patients (66.7%) in the MVC group and 128 of 137 (93.4%) in the PICC group were without VC-related adverse event or dysfunction. The noninferiority of MVC could not be demonstrated (P > .99 for noninferiority).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, MVCs were associated with a significantly higher percentage of patients with VC-related adverse events or dysfunctions and could not be demonstrated as a noninferior alternative to PICCs.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03502980.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e251258"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA Network OpenPub Date : 2025-03-03DOI: 10.1001/jamanetworkopen.2025.0014
Meredith Bock, Siqi Gan, Melissa Aldridge, Krista L Harrison, Kristine Yaffe, Alexander K Smith, John Boscardin, Lauren J Hunt
{"title":"Hospice Use Among Medicare Beneficiaries With Parkinson Disease and Dementia With Lewy Bodies.","authors":"Meredith Bock, Siqi Gan, Melissa Aldridge, Krista L Harrison, Kristine Yaffe, Alexander K Smith, John Boscardin, Lauren J Hunt","doi":"10.1001/jamanetworkopen.2025.0014","DOIUrl":"10.1001/jamanetworkopen.2025.0014","url":null,"abstract":"<p><strong>Importance: </strong>Neurodegenerative disorders are now the most common reason that Medicare beneficiaries enroll in hospice for end-of-life care. People with all-cause dementia have high rates of suboptimal hospice use, but little is known about hospice use patterns in Lewy body disease, which includes both Parkinson disease (PD) and dementia with Lewy bodies (DLB).</p><p><strong>Objective: </strong>To compare patient characteristics, hospice agency characteristics, and patterns of use for beneficiaries with PD and DLB vs Alzheimer disease (AD).</p><p><strong>Design, setting, and participants: </strong>A retrospective cohort study including a 100% sample of national 2010-2020 calendar year Medicare data on hospice enrollees was performed. Data analysis was conducted from November 2023 to May 2024.</p><p><strong>Exposures: </strong>A diagnosis of PD or DLB, compared with AD as the reference group.</p><p><strong>Main outcomes and measures: </strong>Proportion of enrollees with short stays (<7 days), proportion with long stays (>180 days), proportion disenrolled for any reason before death, and disenrollment by type.</p><p><strong>Results: </strong>Of 11 327 324 Medicare beneficiaries enrolled in hospice between 2010 and 2020 who met eligibility criteria (mean [SD] age, 85.2 [7.5] years; 781 763 [63.0%] female), there were 958 182 (8.4%) with a primary diagnosis of AD, 232 864 (2.1%) with PD, and 49 340 (0.4%) with DLB. People with PD were more likely to experience a long stay (odds ratio [OR], 1.15; 95% CI, 1.13-1.16) compared with AD, whereas the odds for those with DLB were not increased. However, people with either PD or DLB were less likely to be disenrolled for extended prognosis compared with AD (OR for DLB, 0.82; 95% CI, 0.79-0.85; OR for PD, 0.86; 95% CI, 0.85-0.88). People with PD were more likely to revoke hospice (OR, 1.29; 95% CI, 1.27-1.32) compared with AD.</p><p><strong>Conclusions and relevance: </strong>In this cohort study of Medicare beneficiaries, hospice use patterns differed by dementia subtype. Higher likelihood of hospice revocation in PD raises important questions about unmet needs and highlights the need for more research around the experience of the end of life in this growing population.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250014"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}